Semaglutide
InjectionWeight Loss
TabletWeight LossIn stock
Wegovy® tablet
FDA-approved oral semaglutide for chronic weight management, the first weight-loss pill in the GLP-1 class. Run a daily-pill Wegovy®-aware program with intake, billing, and refill workflows built in.
Dose
Once daily
Avg. loss · 68 wks
−15.1%
Format
Once-daily oral tablet
Before food
Empty stomach, 30 min before food or oral meds
Rx required
Yes, licensed provider review
Indication
Chronic weight management (approved Dec 2025)
About the medication
The first oral GLP-1 approved for weight management
Approved by the FDA on December 22, 2025 and launched in early January 2026, the Wegovy® tablet is the first oral semaglutide formulation labeled specifically for chronic weight management. In the OASIS 1 trial, adults with overweight or obesity taking oral semaglutide 50 mg once daily lost an average of 15.1% of body weight over 68 weeks.
- Same molecule as injectable Wegovy® in a once-daily tablet form
- Roughly comparable weight outcomes to the 2.4 mg injectable at maintenance
- Requires strict empty-stomach administration, patient education is critical
- Strong fit for patients who reject injections or want a discreet daily routine
Mechanism
GLP-1 receptor agonist, oral SNAC-enabled absorption
Delivery
Once-daily tablet swallowed whole in the morning
Administration
Empty stomach, max 4 oz water, wait 30 min before food or oral meds
Oversight
Every order routed through a licensed provider review
Expected results
Injectable-comparable weight loss in a daily pill format
Based on OASIS 1 phase 3 outcomes (68 weeks, escalation to 50 mg daily). Real-world outcomes depend on adherence to the empty-stomach dosing window.
15.1%
Avg. total body weight loss
at 68 weeks, 50 mg daily
85%
Patients losing ≥5%
at week 68 in OASIS 1
54%
Patients losing ≥15%
at week 68 in OASIS 1
Mean change in body weight
% change from baseline · weeks 0–68
Wegovy® tablet 50 mgPlacebo
At week 68
−15.1%
Wegovy® tablet 50 mg
At week 68
−2.4%
Placebo
Net difference
−12.7 pts
vs. placebo
Illustrative, based on published OASIS 1 outcomes for oral semaglutide 50 mg. Real-world adherence to empty-stomach dosing strongly affects outcomes.
Dosing protocol
Standard titration schedule
Patients step up gradually to improve GI tolerability. This mirrors the OASIS 1 escalation used in the Wegovy® tablet label.
- 1Weeks 1–43 mgInitiation dose, GI tolerance
- 2Weeks 5–87 mgFirst up-titration
- 3Weeks 9–1214 mgTherapeutic ramp
- 4Weeks 13–1625 mgIntermediate escalation
- 5Week 17+50 mgTarget maintenance dose
The Turbopills stack for this program
Everything you need to run a Wegovy® tablet program
Pick the pieces you want. Use your own brand, your own providers, your own price, powered by a single, compliant backend.
Product website & ad landing pages
Turbopills AI Studio — ad images & videos
BetaProvider review & e-Rx
Pharmacy order routing
Refills & auto-ship
Experiments & A/B tests
BetaReady to launch
Launch a daily Wegovy® tablet program in weeks, not quarters.
The platform ships the intake flow, billing, subscriptions, refill workflows, and the operator console your team works in. Bring your licensed providers and pharmacy partners; we wire everything into one backend so you launch in weeks, not quarters.
Marketing and educational content only. Clinical details on this page are summarized from publicly available sources to help operators scope a program — they are not medical advice, dosing instructions, or a recommendation for any individual patient. Real patient care requires a licensed provider and a compliant pharmacy partner; Turbopills provides the software that helps brands run the program around them.
Trademark notice. Wegovy® is a registered trademark of Novo Nordisk A/S. Turbopills is not affiliated with, endorsed by, or sponsored by Novo Nordisk. References to the brand are for educational and operator-scoping purposes only.
Related
